| Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer J Baselga, M Campone, M Piccart, HA Burris III, HS Rugo, T Sahmoud, ... New England Journal of Medicine 366 (6), 520-529, 2012 | 3559 | 2012 |
| Ribociclib as first-line therapy for HR-positive, advanced breast cancer GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, ... New England journal of medicine 375 (18), 1738-1748, 2016 | 2027 | 2016 |
| Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ... New England Journal of Medicine 382 (7), 597-609, 2020 | 1237 | 2020 |
| Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome M Gobert, I Treilleux, N Bendriss-Vermare, T Bachelot, S Goddard-Leon, ... Cancer research 69 (5), 2000-2009, 2009 | 911 | 2009 |
| Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic … T Bachelot, C Bourgier, C Cropet, I Ray-Coquard, JM Ferrero, G Freyer, ... Journal of Clinical Oncology 30 (22), 2718-2724, 2012 | 899 | 2012 |
| Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study T Bachelot, G Romieu, M Campone, V Diéras, C Cropet, F Dalenc, ... The lancet oncology 14 (1), 64-71, 2013 | 877 | 2013 |
| Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas I Ray-Coquard, C Cropet, M Van Glabbeke, C Sebban, A Le Cesne, ... Cancer research 69 (13), 5383-5391, 2009 | 839 | 2009 |
| Genomic characterization of metastatic breast cancers F Bertucci, CKY Ng, A Patsouris, N Droin, S Piscuoglio, N Carbuccia, ... Nature 569 (7757), 560-564, 2019 | 633 | 2019 |
| Dendritic cell infiltration and prognosis of early stage breast cancer I Treilleux, JY Blay, N Bendriss-Vermare, I Ray-Coquard, T Bachelot, ... Clinical Cancer Research 10 (22), 7466-7474, 2004 | 539 | 2004 |
| Breast cancer with synchronous metastases: trends in survival during a 14-year period F Andre, K Slimane, T Bachelot, A Dunant, M Namer, A Barrelier, ... Journal of Clinical Oncology 22 (16), 3302-3308, 2004 | 527 | 2004 |
| Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial NU Lin, V Borges, C Anders, RK Murthy, E Paplomata, E Hamilton, ... Journal of Clinical Oncology 38 (23), 2610-2619, 2020 | 486 | 2020 |
| 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial X Pivot, G Romieu, M Debled, JY Pierga, P Kerbrat, T Bachelot, ... The lancet oncology 14 (8), 741-748, 2013 | 468 | 2013 |
| Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER) F André, T Bachelot, F Commo, M Campone, M Arnedos, V Dieras, ... The lancet oncology 15 (3), 267-274, 2014 | 459 | 2014 |
| Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial S Loi, A Giobbie-Hurder, A Gombos, T Bachelot, R Hui, G Curigliano, ... The Lancet Oncology 20 (3), 371-382, 2019 | 443 | 2019 |
| Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a … A Di Leo, S Johnston, KS Lee, E Ciruelos, PE Lønning, W Janni, ... The Lancet Oncology 19 (1), 87-100, 2018 | 410 | 2018 |
| Mutational profile of metastatic breast cancers: a retrospective analysis C Lefebvre, T Bachelot, T Filleron, M Pedrero, M Campone, JC Soria, ... PLoS medicine 13 (12), e1002201, 2016 | 399 | 2016 |
| Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients T Bachelot, I Ray-Coquard, C Menetrier-Caux, M Rastkha, A Duc, JY Blay British journal of cancer 88 (11), 1721-1726, 2003 | 383 | 2003 |
| EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours E Le Rhun, M Guckenberger, M Smits, R Dummer, T Bachelot, F Sahm, ... Annals of Oncology 32 (11), 1332-1347, 2021 | 372 | 2021 |
| Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression V Sisirak, J Faget, M Gobert, N Goutagny, N Vey, I Treilleux, ... Cancer research 72 (20), 5188-5197, 2012 | 370 | 2012 |
| Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer F André, T Bachelot, M Campone, F Dalenc, JM Perez-Garcia, SA Hurvitz, ... Clinical cancer research 19 (13), 3693-3702, 2013 | 358 | 2013 |
